New funding: At a second when vaccines are on everybody’s thoughts, a Seattle-based biotech firm that has an uncommon strategy to vaccine manufacturing has raised $100 million in a Collection B spherical. The startup creates computer-designed, virus-like particles which can be utilized in vaccines to set off immune responses. The brand new funding follows a $51 million spherical in October 2019. Icosavax has 17 workers.
Extra on the vaccines: Icosavax is engaged on a COVID-19 vaccine, in addition to vaccines to stop much less well-known ailments: respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Early analysis outcomes present that the vaccines elicit sturdy immune responses.
“Based mostly on preclinical information, we consider our vaccine candidates may provide important safety in opposition to main viral causes of pneumonia in older adults the place no licensed vaccines at present exist,” stated Icosavax CEO Adam Simpson, concerning the RSV and hMPV vaccines.
The corporate launched its COVID program in October, supported partly by $10 million from the Invoice & Melinda Gates Basis.
Sturdy ties to the Institute for Protein Design: The corporate is a spinout from the College of Washington’s Institute for Protein Design (IPD). The institute is led by David Baker, who’s an Icosavax co-founder and advisor. Icosavax’s virus-like particle know-how was invented at IPD by Neil King, who serves as chair of the startup’s scientific advisory board.
Simpson was previously the CEO of PvP Biologics, one other IPD spinout, which he oversaw from the corporate’s launch via its sale to the pharmaceutical firm Takeda.
Traders: The funding spherical was led by RA Capital Administration and joined by Janus Henderson Traders, Perceptive Advisors, Viking International Traders, Cormorant Asset Administration, Omega Funds and Surveyor Capital. Others contributing to the spherical embody current buyers Qiming Enterprise Companions USA; Adams Road Companions; Sanofi Ventures; and ND Capital. The spherical included money from a October 2020 funding.